I. Tárkányi

发表

Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin’s lymphoma

Z. Nemes, Z. Simon, Á. Illés, 2008, Pathology & Oncology Research.

In vitro and in vivo activity of 4-thio-uridylate against JY cells, a model for human acute lymphoid leukemia.

L. Fésüs, G. Vámosi, I. Juhász, 2011, Biochemical and biophysical research communications.

Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo‐oligonucleotide

E. Ségal-Bendirdjian, G. Vámosi, S. Damjanovich, 2005, FEBS letters.

Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study)

Á. Illés, R. Szász, G. Ujj, 2018, Pathology & Oncology Research.

Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths

Guoqiang Chen, M. Lanotte, E. Ségal-Bendirdjian, 2006, Journal of Cell Science.

Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death

M. Lanotte, E. Ségal-Bendirdjian, J. Hillion, 2005, Leukemia.

Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.

J. Aradi, I. Tárkányi, 2008, Biochimie.

Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells

M. Lanotte, E. Ségal-Bendirdjian, A. Karniguian, 2010, Leukemia.

Pharmacological regulation of telomerase, induction of telomerase dependent cell death using chimeric oligonucleotides or all-trans-retinoic-acid/arsenic-trioxide combination treatment

I. Tárkányi, 2005 .

Telomeres and telomerase: Pharmacological targets for new anticancer strategies?

M. Lanotte, E. Ségal-Bendirdjian, J. Hillion, 2006, Current cancer drug targets.